Want to see REPL full AI Analyst Report?
Replimune Group (REPL) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Nivolumab, Ipilimumab, Rp2 | Metastatic Uveal Melanoma | phase2AndPhase3 | Recruiting | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | Aug 29, 2024 | ― |
| Pembrolizumab, Nivolumab, Nivolumab + Relatlimab, Vusolimogene Oderparepvec, Single-Agent Chemotherapy | Advanced Melanoma | Phase III | Recruiting | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] | Jan 29, 2024 | ― |
| Bevacizumab, Atezolizumab, Rp2, Rp3 | Refractory Metastatic Colorectal Cancer, Pmmr, Mss | Phase II | Active Not Recruiting | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | Feb 08, 2023 | ― |
| Nivolumab, Rp3, Ccrt(Concurrent Chemoradiation Therapy), Carboplatin And Paclitaxel | Squamous Cell Carcinoma Of Head And Neck, Locally Advanced Head And Neck Squamous Cell Carcinoma, Recurrent Head And Neck Squamous Cell Carcinoma | Phase II | Withdrawn | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | Feb 08, 2023 | ― |
| Bevacizumab, Durvalumab, Atezolizumab, Rp2 | Hepatocellular Carcinoma, Biliary Tract Cancer | Phase II | Recruiting | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | Feb 08, 2023 | ― |
| Nivolumab, Rp3 | Advanced Solid Tumor | Phase I | Active Not Recruiting | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours | Jan 25, 2021 | ― |
| Rp1, Intra-Tumoral Injection, Oncolytic Virus | Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | phase1AndPhase2 | Recruiting | A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies | Apr 14, 2020 | ― |
| Nivolumab, Rp2 | Cancer | Phase I | Recruiting | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | Mar 17, 2020 | ― |
| Nivolumab, Rp1 | Cancer, Nsclc, Cutaneous Melanoma, Melanoma (Skin), Microsatellite Instability, Mismatch Repair Deficiency, Non-Melanoma Skin Cancer | Phase II | Recruiting | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab | Dec 05, 2018 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Nivolumab, Ipilimumab, Rp2 | phase2AndPhase3 | Metastatic Uveal Melanoma | Recruiting | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | Aug 29, 2024 | ― |
| Pembrolizumab, Nivolumab, Nivolumab + Relatlimab, Vusolimogene Oderparepvec, Single-Agent Chemotherapy | Phase III | Advanced Melanoma | Recruiting | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] | Jan 29, 2024 | ― |
| Bevacizumab, Atezolizumab, Rp2, Rp3 | Phase II | Refractory Metastatic Colorectal Cancer, Pmmr, Mss | Active Not Recruiting | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | Feb 08, 2023 | ― |
| Nivolumab, Rp3, Ccrt(Concurrent Chemoradiation Therapy), Carboplatin And Paclitaxel | Phase II | Squamous Cell Carcinoma Of Head And Neck, Locally Advanced Head And Neck Squamous Cell Carcinoma, Recurrent Head And Neck Squamous Cell Carcinoma | Withdrawn | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | Feb 08, 2023 | ― |
| Bevacizumab, Durvalumab, Atezolizumab, Rp2 | Phase II | Hepatocellular Carcinoma, Biliary Tract Cancer | Recruiting | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | Feb 08, 2023 | ― |
| Nivolumab, Rp3 | Phase I | Advanced Solid Tumor | Active Not Recruiting | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours | Jan 25, 2021 | ― |
| Rp1, Intra-Tumoral Injection, Oncolytic Virus | phase1AndPhase2 | Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | Recruiting | A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies | Apr 14, 2020 | ― |
| Nivolumab, Rp2 | Phase I | Cancer | Recruiting | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | Mar 17, 2020 | ― |
| Nivolumab, Rp1 | Phase II | Cancer, Nsclc, Cutaneous Melanoma, Melanoma (Skin), Microsatellite Instability, Mismatch Repair Deficiency, Non-Melanoma Skin Cancer | Recruiting | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab | Dec 05, 2018 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Replimune Group (REPL) have in its pipeline
Replimune Group REPL is currently developing the following drugs: Nivolumab, Ipilimumab, Rp2, Pembrolizumab, Nivolumab, Nivolumab + Relatlimab, Vusolimogene Oderparepvec, Single-Agent Chemotherapy, Bevacizumab, Atezolizumab, Rp2, Rp3, Nivolumab, Rp3, Ccrt(Concurrent Chemoradiation Therapy), Carboplatin And Paclitaxel, Bevacizumab, Durvalumab, Atezolizumab, Rp2, Nivolumab, Rp3, Rp1, Intra-Tumoral Injection, Oncolytic Virus, Nivolumab, Rp2, Nivolumab, Rp1. These drug candidates are in various stages of clinical development as the company works toward FDA approval.